{"id":5486,"date":"2026-10-13T08:06:47","date_gmt":"2026-10-13T02:36:47","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-13\/"},"modified":"2026-10-13T09:07:46","modified_gmt":"2026-10-13T03:37:46","slug":"sunpharma-share-price-today-2026-10-13","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-13\/","title":{"rendered":"Sun Pharma in Focus After INR 10,000 Crore NCD Approval and Director Resignation | 13 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"premarket\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: SUNPHARMA<\/strong> \u00b7 13 October 2026 \u00b7 Pre-market update<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Previous close<\/div>\n<div>\u20b91,760.00<\/div>\n<\/div>\n<div>\n<div>Previous day change<\/div>\n<div>+0.01%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,776.80 \/ \u20b91,751.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>13.46 lakh<\/div>\n<\/div>\n<div>\n<div>Previous trading day<\/div>\n<div>9 October 2026<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Sun Pharmaceutical Industries Limited is in focus ahead of the market open following its board meeting outcome on October 12, 2026. The company announced the approval of raising up to INR 10,000 Crore via Non-Convertible Debentures and noted the resignation of Non-Executive Independent Director Mr. Gautam Doshi.<\/li>\n<li>The board of directors approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis in one or more tranches for an aggregate amount not exceeding INR 10,000 Crore. The finance committee has been authorized to determine tranche-specific terms.<\/li>\n<li>Trading volume was 0.83 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Sun Pharmaceutical Ind L Company News Before Market Open<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Sun Pharmaceutical Industries Limited is in focus ahead of the market open following its board meeting outcome on October 12, 2026. The company announced the approval of raising up to INR 10,000 Crore via Non-Convertible Debentures and noted the resignation of Non-Executive Independent Director Mr. Gautam Doshi.<\/p>\n<p class=\"wt-copy\">The board-approved INR 10,000 Crore non-convertible debentures issuance sets up significant debt-capital fundraising activity. The departure of independent director Gautam Doshi alters board committee structures. Prior session context shows the stock closed at 1760.0 on October 9, 2026, amid broader 20-day downward price pressure.<\/p>\n<p class=\"wt-copy\">13.46 lakh shares traded on 9 October 2026. This compares with a 20-day average daily volume of 16.15 lakh shares (0.83 times). The five-day average daily volume was 15.68 lakh shares.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Company-specific context<\/div>\n<div class=\"wt-card-body\"><strong>Board Approves Non-Convertible Debentures Issuance up to INR 10,000 Crore and Notes Director Resignation<\/strong><\/p>\n<p class=\"wt-copy\">The board-approved INR 10,000 Crore non-convertible debentures issuance sets up significant debt-capital fundraising activity. The departure of independent director Gautam Doshi alters board committee structures. Prior session context shows the stock closed at 1760.0 on October 9, 2026, amid broader 20-day downward price pressure.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Sun Pharma Board Approves NCD Issuance up to INR 10,000 Crore<\/div>\n<div class=\"wt-card-date\">12 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The board of directors approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis in one or more tranches for an aggregate amount not exceeding INR 10,000 Crore. The finance committee has been authorized to determine tranche-specific terms.<\/p>\n<p class=\"wt-copy\">The capital raise plans indicate strategic funding maneuvers that will be closely analyzed by market participants.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Non-Executive Independent Director Gautam Doshi Resigns<\/div>\n<div class=\"wt-card-date\">12 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mr. Gautam Doshi has resigned from his position as a Non-Executive, Independent Director of the company effective October 12, 2026, citing personal commitments and confirming no other material reasons.<\/p>\n<p class=\"wt-copy\">Board composition changes in key independent oversight roles attract governance-related focus from investors.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Outcome of Board Meeting<\/div>\n<div class=\"wt-card-date\">13 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Outcome of the Board Meeting held on 12 October 2026<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_12102026195625_BMOutcome12October2026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">54.48%<\/div>\n<div class=\"wt-note\">54.48% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">14.53%<\/div>\n<div class=\"wt-note\">15.93% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">36.71%<\/div>\n<div class=\"wt-note\">37.04% on 31 March 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1694893_17072026122439_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 12.84% on 30 June 2026. This compares with 11.96% on 31 March 2026, a change of +0.88 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 49 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Icici Prudential Value Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">8.92 crore shares \u00b7 3.72%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Sbi Nifty 50 Etf<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">5.67 crore shares \u00b7 2.36%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd-A\/C Nippon India Large Cap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">3.31 crore shares \u00b7 1.38%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1694893_17072026122439_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mutb400045794<\/div>\n<div class=\"wt-card-date\">24 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 1.54 lakh shares \u00b7 \u20b91,868.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mtbj400045828<\/div>\n<div class=\"wt-card-date\">24 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 1.54 lakh shares \u00b7 \u20b91,868.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Trading volumes and institutional participation following the debt-raising announcement.<\/li>\n<li>Further disclosures regarding the tranche-specific terms and timelines of the NCD issuances.<\/li>\n<li>Price action relative to the 20-day average close of 1829.09 and support levels near the prior session low of 1751.0.<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-07\/\">Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Falling 1.28% | 7 October 2026 \u2014 7 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-09-30\/\">Why Sun Pharma Shares Fell 2.60% Today Amid Pharma Sector Weakness | 30 September 2026 \u2014 30 September 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/sunpharma\/\">More Sun Pharmaceutical Ind L news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Sun Pharmaceutical Ind L company news?<\/h3>\n<p class=\"wt-copy\">The board of directors approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis in one or more tranches for an aggregate amount not exceeding INR 10,000 Crore. The finance committee has been authorized to determine tranche-specific terms.<\/p>\n<h3>How strong was Sun Pharmaceutical Ind L\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">13.46 lakh shares traded, 0.83 times the 20-day average daily volume. The price and volume data are dated 9 October 2026.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-13\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-13\/\"}, \"headline\": \"Sun Pharma in Focus After INR 10,000 Crore NCD Approval and Director Resignation | 13 October 2026\", \"description\": \"Sun Pharmaceutical Industries in focus pre-market after board approves up to INR 10,000 Crore NCD issuance and notes independent director Gautam Doshi's.\", \"datePublished\": \"2026-10-13T02:36:47Z\", \"dateModified\": \"2026-10-13T09:07:37.642397+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/sunpharma-company-news-2026-10-13.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Resignation of Director\/KMP\/SMP\",\"summary\":\"Resignation of Director\/KMP\/SMP\",\"source\":\"NSE\",\"published\":\"12-Oct-2026 20:34:43\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNPHARMA_ROID_100278_KMP_Doc.zip\",\"disclosure_text\":\"\"},{\"title\":\"Resignation\",\"summary\":\"Resignation of Director of the Company\",\"source\":\"NSE\",\"published\":\"12-Oct-2026 20:05:00\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_12102026200413_BMOutcome12October2026.pdf\",\"disclosure_text\":\"Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA Reaching People. Touching Lives 12 October 2026 National Stock Exchange of India Limited BSE Limited NSE Code: SUNPHARMA BSE Code: 524715 Outcome of the Board Meeting held today, i.e., 12 October 2026 F urther to the communication dated 07 October 2026, this is to inform that the meeting of the Board of Directors of the Company (\u201cBoard\u201d) was held today, i.e. 12 October 2026, which commenced at 05:00 P.M. and concluded at 05:50 P.M., IST. The Board, inter alia, considered and approved the following: 1. Issuance of Non-Convertible Debentures T he Board of Directors has approved the issuance of listed, rated, unsecured, redeemable non- convertible debentures (\\\"NCDs\\\"), on a private placement basis, in one or more tranches and\/or series, for an aggregate amount not exceeding INR 10,000 Crore. T he Board has also approved the related issuance framework and authorised the Finance Committee to determine and approve the tranche-specific terms and conditions of the NCDs, including matters relating to their issuance, allocation and allotment, within the framework approved by the Board. T he disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 shall be made at the appropriate stage, upon issuance and\/or allotment of the NCDs. 2. Resignation of Mr. Gautam Doshi M r. Gautam Doshi (DIN: 00004612) has tendered his resignation as a Non-Executive, Independent Director of the Company with effect from 12 October 2026, citing personal reasons. He has confirmed that there are no material re asons for his resignation other than those stated in his resignation letter. Consequent upon his resignation, he has also ceased to hold positions on the Committees of the Board of Directors of the Company. T he Board of Directors has taken note of the resignation of Mr. Gautam Doshi and placed on record its sincere appreciation for the valuable guidance and contributions made by him during his tenure as an Independent Director of the Company. The details required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in Annexure A and the resignation letter of Mr. Gautam Doshi is enclosed herewith as Annexure B. Fo r Sun Pharmaceutical Industries Limited ( Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA Reaching People. Touching Lives Annexure A D isclosure under Para (A) of Part (A) of Schedule III to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Sr. No. Particulars 1 Name Mr. Gautam Doshi (DIN: 00004612) 2 Reason for change viz. resignation Resignation from the position of Non - Executive Independent Director of the Company with immediate effect due to his personal commitments. 3 Date of cessation 12 October 2026 4 Brief profile (in case of appointment); Not Applicable 5 Disclosure of relationships between directors (in case of appointment of a director) Not Applicable 6 Letter of resignation along with detailed reason for resignation Enclosed as Annexure B 7. Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any Not Applicable 8. The independent director shall, along with the detailed reasons, also provide a confirmation that there are no other material reasons other than those provided Mr. Gautam Doshi confirmed that there are no material reasons for his resignation other than those mentioned in her resignation letter. Annexure B\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Outcome of the Board Meeting held on 12 October 2026\",\"source\":\"NSE\",\"published\":\"12-Oct-2026 19:57:07\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_12102026195625_BMOutcome12October2026.pdf\",\"disclosure_text\":\"Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA Reaching People. Touching Lives 12 October 2026 National Stock Exchange of India Limited BSE Limited NSE Code: SUNPHARMA BSE Code: 524715 Outcome of the Board Meeting held today, i.e., 12 October 2026 F urther to the communication dated 07 October 2026, this is to inform that the meeting of the Board of Directors of the Company (\u201cBoard\u201d) was held today, i.e. 12 October 2026, which commenced at 05:00 P.M. and concluded at 05:50 P.M., IST. The Board, inter alia, considered and approved the following: 1. Issuance of Non-Convertible Debentures T he Board of Directors has approved the issuance of listed, rated, unsecured, redeemable non- convertible debentures (\\\"NCDs\\\"), on a private placement basis, in one or more tranches and\/or series, for an aggregate amount not exceeding INR 10,000 Crore. T he Board has also approved the related issuance framework and authorised the Finance Committee to determine and approve the tranche-specific terms and conditions of the NCDs, including matters relating to their issuance, allocation and allotment, within the framework approved by the Board. T he disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 shall be made at the appropriate stage, upon issuance and\/or allotment of the NCDs. 2. Resignation of Mr. Gautam Doshi M r. Gautam Doshi (DIN: 00004612) has tendered his resignation as a Non-Executive, Independent Director of the Company with effect from 12 October 2026, citing personal reasons. He has confirmed that there are no material re asons for his resignation other than those stated in his resignation letter. Consequent upon his resignation, he has also ceased to hold positions on the Committees of the Board of Directors of the Company. T he Board of Directors has taken note of the resignation of Mr. Gautam Doshi and placed on record its sincere appreciation for the valuable guidance and contributions made by him during his tenure as an Independent Director of the Company. The details required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in Annexure A and the resignation letter of Mr. Gautam Doshi is enclosed herewith as Annexure B. Fo r Sun Pharmaceutical Industries Limited ( Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA Reaching People. Touching Lives Annexure A D isclosure under Para (A) of Part (A) of Schedule III to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Sr. No. Particulars 1 Name Mr. Gautam Doshi (DIN: 00004612) 2 Reason for change viz. resignation Resignation from the position of Non - Executive Independent Director of the Company with immediate effect due to his personal commitments. 3 Date of cessation 12 October 2026 4 Brief profile (in case of appointment); Not Applicable 5 Disclosure of relationships between directors (in case of appointment of a director) Not Applicable 6 Letter of resignation along with detailed reason for resignation Enclosed as Annexure B 7. Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any Not Applicable 8. The independent director shall, along with the detailed reasons, also provide a confirmation that there are no other material reasons other than those provided Mr. Gautam Doshi confirmed that there are no material reasons for his resignation other than those mentioned in her resignation letter. Annexure B\"}],\"shareholding_snapshot\":{\"promoter_pct\":54.48,\"public_pct\":45.52,\"fii_pct\":14.53,\"dii_pct\":22.18,\"mf_pct\":12.84,\"institutional_pct\":36.71,\"noninst_pct\":8.81,\"mf_scheme_count\":49,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Icici Prudential Value Fund\",\"shares\":89198583,\"pct\":3.72},{\"name\":\"Sbi Nifty 50 Etf\",\"shares\":56689578,\"pct\":2.36},{\"name\":\"Nippon Life India Trustee Ltd-A\/C Nippon India Large Cap Fund\",\"shares\":33125559,\"pct\":1.38}],\"period\":\"30-JUN-2026\",\"submission_date\":\"17-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1694893_17072026122439_WEB.xml\",\"previous_period\":\"31-MAR-2026\",\"previous_promoter_pct\":54.48,\"previous_fii_pct\":15.93,\"previous_dii_pct\":21.11,\"previous_mf_pct\":11.96,\"previous_institutional_pct\":37.04,\"previous_mf_scheme_count\":47,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"24 Jun, 2026\",\"party\":\"The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mutb400045794\",\"side\":\"Buy\",\"quantity\":\"154424\",\"price\":\"1,868\",\"source\":\"Public market-data page\",\"value\":\"\u20b928.85 Cr\"},{\"deal_type\":\"Block\",\"date\":\"24 Jun, 2026\",\"party\":\"The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mtbj400045828\",\"side\":\"Sell\",\"quantity\":\"154424\",\"price\":\"1,868\",\"source\":\"Public market-data page\",\"value\":\"\u20b928.85 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sun Pharmaceutical Industries in focus pre-market after board approves up to INR 10,000 Crore NCD issuance and notes independent director Gautam Doshi&#8217;s.<\/p>\n","protected":false},"author":1,"featured_media":5485,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Sun Pharma in Focus After INR 10,000 Crore NCD Approval and Director Resignation | 13 October 2026","_witty_meta_description":"Sun Pharmaceutical Industries in focus pre-market after board approves up to INR 10,000 Crore NCD issuance and notes independent director Gautam Doshi's.","_witty_primary_phrase":"Sun Pharmaceutical Industries NCD issuance","_witty_reason_label":"Board Approves Non-Convertible Debentures Issuance up to INR 10,000 Crore and Notes Director Resignation","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[199],"class_list":["post-5486","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-sunpharma"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=5486"}],"version-history":[{"count":2,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5486\/revisions"}],"predecessor-version":[{"id":5565,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5486\/revisions\/5565"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/5485"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=5486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=5486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=5486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}